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1. Introduction  
Tuberculosis (TB) is an illness that results from infection with Mycobacterium tuberculosis 
(MTB). This aerobic bacillus have the cell wall with a high lipid contend which result in a 
high degree of lipophilicity and resistance to alcohol, acids, alkali and some disinfectants. 
TB is the leading worldwide cause of mortality resulting from an infectious bacterial agent. 
The World Health Organization (WHO) estimates that almost one-third of world’s 
population is infected with MTB, with 8.9-9.9 million incident cases by year (WHO, 2010).  
MTB is epidemiologically characterized by high rate infectivity, so the one-third of latent 
infection population which remains a reservoir from mycobacterium is the major obstacle to 
the total control of the disease. In normal conditions, the bacteria has the ability to live in 
balance with immune response but in situations such as genetic impaired, intercurrent 
diseases (i.e. AIDS), malnutrition and medical interventions could occur an imbalance, and 
the MTB multiplies rapidly developing the disease (Gideon & Flynn, 2011). 
The multidrug-resistant tuberculosis (MDR-TB) is another important problem to control TB 
worldwide. It has been reported that include patients who have never been treated with any 
TB drug demonstrated resistance. According to WHO, MDR-TB is responsible for 
approximately 460 thousand new cases per year and for about 740 thousand new patients 
infected by both MTB and HIV/AIDS. Recent estimates show that 10% of all new TB 
infections are resistant to at least one anti-TB drug. 
The actual drug therapy for tuberculosis has involved administration of multiple drugs 
because it was clear that monotherapy led to the development of resistance (Barry & 
Blanchard, 2010). Short course chemotherapy involves taking isoniazid and rifampicin for 6 
months with pyrazinamide and ethambutol supplement in the first 2 months (Ma et al., 
2010).  
For multidrug-resistance (MDR) and extensively drug resistance (XDR) are used  the 
combination of first line drugs and seconde line drugs as aminoglycosides (amikacyn and 
kanamicyn), polypetides(capreomicyn, viomycin, envyomicin), fluoroquinolones (ofloxacin, 
levofloxacin, moxifloxacin, gatifloxacin), thioamides (ethionamide, prothionmide), 
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cycloserine, terizidone, para-aminosalicylic acid. This chemotherapy is less effective, longer , 
expensive and more toxic than the short course therapy (Ma et al., 2010).  
Third line drugs include rifabutin, macrolides (clarithromicin), linezolid, thiacetazone, 
thioridazine, arginine, vitamin D are still being developed, have less or unproven efficacy 
and are very expensive (Laloo & Ambaram, 2010).  
Since the discovery of rifampicin in 60’ there is no more drugs developed to treat tuberculosis. 
Considering the increase of resistant the discovery of new antitubercular drugs is urgent. A 
new anti-TB drug must possess some characteristics such as wide spectrum of action, adequate 
posology to allow the patient compliance, short duration of treatment and adequate 
pharmacokinetic properties (half-life, decreased drug-drug interaction among others). 
Among the strategies to introduce a new drug in the market, the molecular modification 
approach has showed to be promising. Several drugs in the market was developed using 
this strategy. This chapter aiming to discuss some strategies of molecular modification such 
as prodrug approach, molecular hybridization and biosisoterism in order to design and 
develop new drugs against M. tuberculosis.  
2. Molecular modification 
Molecular modification is an chemical alteration in a molecule which could be a lead 
compound or a drug aiming to enhance its pharmaceutical, pharmacokinetic or 
pharmacodynamics. This strategy has been used by medicinal chemistry by several years 
allowing the discovery of many available drugs present in the market. Among molecular 
modification used we can cite: prodrug approach, molecular hybridization and 
bioisosterism. Each one of this strategy will be introduced highlighting their application in 
TB drug discovery. 
2.1 Prodrug approach 
The first definition of prodrug was introduced by Albert in 1958 which define prodrug as 
“any compound that undergoes biotransformation prior to exhibit its pharmacological 
effects” (Albert, 1958). In order to improve this definition, Haper (1959) proposed the term 
latentiation. Drug latentiation is understood as “the chemical modification of biologically 
active compound to form a new compound that, upon in vivo enzymatic attack, will liberate 
the parent compound”. In general the prodrugs could be classified into two main classes:  
bioprecursors and carrier prodrugs. 
Bioprecursors is a molecular modification strategy that generates a new compound- 
substrate for the metabolizing enzymes that after this biotransformation demonstrate 
biological activity. This approach generally does not use carriers. Several examples of drugs 
are available in the market used this strategy such as sulindac, acyclovir, losartan among 
others (Silva et al., 2005). 
Carriers’ prodrugs are designed using labile linkage between a carrier group and an active 
compound. This prodrug after chemical or biological biotransformation releases the parental 
drug responsible for the biological activity (Figure 01). The prodrug, per se, is usually 
inactive or less active than parental drug.  
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The carrier selection could explore two strategies: the first one is use an inactive carrier 
(non-toxic) and the second one use active compounds in order to obtain synergic effect. In 
the last strategy we could classified as mutual prodrugs or codrugs. In both situations is 
expected that then active compound (s) should be release with adequate kinetic hydrolysis 
reaction (Silva et al., 2005). 
 
Fig. 1. Prodrug approach. The drug could present some inadequate characteristic related to 
pharmaceutical, pharmacokinetic or pharmacodynamic phase. As the drug is not able to win 
barriers due this inadequate characteristic the effect is not observed or is decreased. The use 
of the prodrug approach can solve this problem. After biotransformation the drug can act 
demonstrating the optimization of the effect.   
The prodrug approach has been used by several researches in order to find new 
antitubercular compounds (Chung et al., 2007).  
Some antitubercular drugs such as pyrazinamide, isoniazide and ethionamide could be 
considered as bioprecursor prodrugs.  
Pyrazinamide is bioconverted by intracellular antimicobacterial pyrazinamidase to pyrazinoic 
acid (Figure 2). This last one can decrease the pH surroundings the M. tuberculosis preventing 
growth. Furthermore, pyrazinoic acid can across through mycobacterial membrane allows 
lowering of cytoplasmatic pH leading to the disruption of membrane transport and energy 
depletion (Zhang, 2005). Pyrazinamide resistance could be found in tubercle bacillus that 
present mutation encoding pyrazinamide/nicotinamidase (pncA). 
 
Fig. 2. Pyrazinamide conversion to pyrazinoic acid. 
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Several pyrazinoic prodrugs with increased lipophilic properties have demonstrated activity 
against M. tuberculosis. Some substituted pyrazinoic esters demonstrated 100-fold more 
active than pyrazinamide against M. tuberculosis with high plasma stability (Figure 3) 
(Cynamon et al., 1995).  
 
Fig. 3. Chemical structures of some substituted pyrazinoic esters. 
Other pyrazinoic and quinoxaline esters derivatives were prepared and evaluated against 
M. tuberculosis. The compounds 4-acetoxy-benzyl esters of pyrazinoic acid and 4’-
acetoxybenzyl 2-quinoxalinecarboxylate demonstrated MIC values of 1-6,25 μg/mL (Seitz et 
al., 2002) (Figure 4). 
 
Fig. 4. Pyrazinoic and quinoxaline esters derivatives. 
Another interesting study about pyrazinoic prodrugs was performed by Simões and co-
workers (2009). The authors synthesized and compared a series of esters and amides 
prodrugs based on pyrazinamide structure (Figure 5). All compounds demonstrated higher 
lipophilicity (log P) than pirazinamide .The esters derivatives demonstrated better in vitro 
activity against M. tuberculosis (MIC = 10-20 μg/mL) than amide derivatives (MIC = > 800 
μg/mL) with suitable stability in presence of plasma. 
 
Fig. 5. Ester and amide derivatives of pyrazinoic acid synthesized by Simôes and co-workers 
(2009).  
The use of prodrug approach to obtain new esters prodrugs such as pyrazinamide 
analogues seems to be an important strategy to discovery new drugs with improved 
pharmacokinetic and pharmacodynamic properties. 
The isoniazide,  a first line drug to the treatment of M. tuberculosis, was discovered in 1950.  
Isoniazid is a prodrug that is activated through an oxidation reaction catalyzed by the 
enzyme katG which demonstrate catalase-peroxidase activity. After conversion, the drug is 
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biotransformed into reactive species capable to acylate an enzyme system found in the 
mycobacterium. It has been proposed that one of this system is the enzyme inhA which is 
involved in the biosynthesis of mycolic acids (Mdluli et al., 1996). So, after activation by 
KatG the isonicotinoyl radical couples with NADH leading to adduct and inhibiting Inha.  
One of the most problems with antitubercular therapy is the patient compliance and the 
long term therapy involving the use of several drugs. In order to decrease problems with 
therapy adhesion mutual prodrugs (or codrugs) have been reported. Using the prodrug 
approach it was reported the combination of 4-amino-salicylic acid (PAS) – a second line 
drug in the treatment, with isoniazide. The PAS treatment presents some inconvenience 
such as gastrointestinal irritation effects and inadequate bioavailability due to rapid phase II 
metabolism. In the other hand, isoniazide is rapidly absorbed after oral administration and 
quickly metabolized to inactive products (acetylhydrazide, diacetylhydrazide, N-
acetylisoniazide and hydrazine) (Katleen, 1999). This metabolism reaction (acetylation) is 
reduce when PAS is previously administered, increasing half-life of isoniazide. So, using the 
prodrug approach it was proposed the association of both drugs into mutual prodrug in 
order to reduce gastrointestinal toxicity and extensive metabolism of PAS, reduce intestinal 
acetylation of isoniazid and increase the duration of drugs actions. All these hypotheses 
were confirmed after in vitro and in vivo studies (Figure 6) (Prateek et al., 2007). 
 
Fig. 6. Chemical structure of the mutual prodrug proposed by Prateek and co-workers (2007). 
In order to decrease the toxicity and prolonged half-life of isoniazide, polymeric prodrugs 
were synthesized and evaluated. Micellar systems of polyethyleneglycol-poly(aspartic acid) 
copolymer and N-methylene phosphonic chitosan were used as carrier to obtain isoniazid 
prodrugs. The micellar prodrugs demonstrated activity against M. tuberculosis (Silva et al., 
2001).  
The same polymeric prodrugs approach was also explore to design norfloxacin derivatives. 
It was considered that the use of mannosyl ligands as carriers that can be used to target 
macrophages increasing the drug levels in this cell (Gordon & Rabinowitz, 1989; Roseeuw et 
al., 2003).  
Ethionamide is a prodrug which similar mechanism of action of isoniazide. After oxidation 
by catalase-peroxidase the drug is bioconverted to an active acylating agent, ethionamide 
sulfoxide, which inactive inhA enoyl reductase (Figure 7) (Johnsson et al., 1995).   
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Fig. 7. Mechanism of action of ethionamide. 
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The association of TB and HIV infection is dramatic. The immune system is weakened in 
HIV patients allowing reactivation of latent TB and makes these patients more susceptible to 
drug-resistant strains.  It has been estimated that two-thirds of the patients diagnosed with 
TB are also HIV seropositive (Shindikar, 2005). The usual treatments of HIV use nucleoside 
analogs (i.e. zidovudine) associated with other drugs. In this context, mutual prodrugs of 
antimycobacterial agents (such as isoniazid, norfloxacin and ciprofloxacin) and HIV 
nucleoside analogs (such as zidovudine, stavudine and lamivudine) were synthesized and 
evaluated. The zidovudine prodrugs were assayed at 6.25 μg/mL against M. tuberculosis 
strain H37Rv and demonstrated 99% inhibition (with fluoquinolones derivatives) and 90% 
of inhibition (with isoniazide) (Figure 8).  The compounds also have inhibited HIV-1 
replication (Sriram et al., 2005; Sriram et al., 2004). 
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Fig. 8. Zidovudine prodrugs. 
2.2 Molecular modification 
The “one-target-one-drug” paradigm conducted the drug design on 20th century. Although 
very drugs used in therapy have been designed using this approach for a one drug for a 
single target, many diseases remains inadequately treated today. Considering that this 
approach fails to treat some diseases, the drug discovery explores the hybridization between 
molecules in order to modulate multiple targets. The molecular hybridization can be useful 
to improve the main unsuccessful causes of fail in drug discovery such as lack of efficacy 
and poor safety (Morphy & Rankovic, 2006). 
Nowadays there are different approaches to multiple target therapy used mainly in 
unresponsive patient’s conditions such as: a) use of two or more individual tablets (or other 
formulation); b) use of fixed dose combination therapy which two or more drugs are 
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combined in a single tablet (or other kind of formulation); c) use of single molecular entity 
which combine multiple targets actions. The first strategy has the disadvantage of 
inadequate compliance for the patients once they will have to use several drugs during the 
day in order to control some symptoms. Example of this kind of situation could be 
represented by hypertension or diabetes treatment. When someone compares the second 
and third strategies one important difference is that the use of a single chemical entity 
reduce the risk of drug-drug interaction and allows obtaining new compounds that can be 
patented. However, the challenge to design a compound multiple ligand with adequate 
ratio to different receptors is high. On the other hand, the combination of drugs in the same 
formulation favours fast development in order to obtain new commercial product by the 
pharmaceutical companies and it allows prolonged patent life of some old drugs. 
Superiority of combination and drug-drug interaction studies must be performed in this 
kind of strategy (Morphy & Rankovic, 2007). 
Schematically, the Figure 9 shows the use of molecular hybridization strategy. The drug A 
interacts only with the receptor A. The drug B interacts only with the receptor B.  It is 
prohibitive the interaction between drug A and receptor B (and vice versa) but is possible to 
design compounds that can interact with both receptors contributing synergically for a 
desire effect. 
 
Fig. 9. Molecular hybridization strategy – analogy to “lock-key” model. 
The drug design of hybrid compound must consider three different situations: a) the desire 
subunits are linked by a spacer agent; b) both subunits are linked without spacer agent and 
they are fused; c) the desired activities are merged in a new structure. The Figure 10 
represents these different situations in order to design a new drug. 
The combination of multiple actions in the same drug is an interesting strategy in 
tuberculosis treatment in order to contribute to therapy compliance, improve the activity 
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and reduce resistance. One fruitful example using this strategy could be represented by 
Figure 11 which demonstrated the use molecular hybridization of isoniazid and one 
quinolone derivative to increase the antimycobacterial activity of the novel compounds. This 
compound was able to maintain high survival rate reducing in vivo the colony-forming unit 
(CFU) with little few lung lesion and reduce splenomegaly (Shindikar & Viswanathan, 
2005). 
 
Fig. 10. Different hybrid compounds obtained by molecular hybridization. 
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Fig. 11. Molecular hybridization between fluorquinole and isoniazid. 
Similar molecular hybridization approach was performed using a fluorquinole derivative 
and pyrazinamide through Mannich bases. The compounds obtained demonstrated in vitro 
and in vivo antitubercular activity. The compound presented in the Figure 12 demonstrated 
higher log P than pyrazinamide. The log P is an important property to be evaluated in novel 
effective compounds due to lipophilic characteristics of the M. tuberculosis wall. In vitro 
studies showed that the compound was more active than pyrazinamide demonstrating 
important activity against multi drug resistant M. tuberculosis. Furthermore, the compound 
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was able to decrease thorough in vivo studies the bacterial load in lung and spleen tissues 
(Sriram et al., 2006). This result shows that the use of this approach can increase the activity 
of compounds. 
 
Fig. 12. Molecular hybridization between fluorquinole and pyrazinamide. 
Some phthalimide derivatives obtained through molecular hybridization between 
thalidomide and dapsone designed to be active against M. leprae was evaluated against M. 
tuberculosis. The compounds demonstrated in vitro activity with selective index higher than 
80. This hybridization strategy shows to be promising in discovery compounds with wide 
spectrum of action in Mycobacterium sp (Santos et al., 2009). 
2.3 Bioisosterism 
The term isosterism was first definied by Languimuir in 1919 as atoms or organic or 
inorganic molecules which possess the same number and/or arrangement of electrons 
examples such as C=O and N=N; CO2 and NO2 (Burger, 1991). Grimm formulated in 1925, 
the hydride displacement law which explain that the addition of hydrogen to an atom 
confers properties of the next highest atomic number (i.e. the fluorine anion F- and the 
hydroxyl anion HO- present some analogies according to Grimm law) (Grimm, 1925). 
Erlenmeyer proposed the definition of isosteres as elements, molecules or ions which 
present the same number of electrons at the valence level expanding the definition 
(Erlenmeyer, 1932). 
Currently bioisosteres is understood as groups or molecules which have a chemical and 
physical similarity producing broadly similar biological effects (Thornber, 1957). Burger 
classified and subdivided bioisosteres in two broad categories: classic and non-classic 
(Burger, 1970). The classical bioisosteres is subdivided in: a) monovalent atoms or groups; b) 
divalent atoms or groups; c) trivalent atoms or groups; tetravalent atoms and e) ring 
equivalents (Table 1). 
The non-classical bioisosteres do not present the steric and electronic definition of classical 
isosteres, furthermore they do not have the same number of atoms of the substituent or 
moiety replaced. Among non-classical bioisosteres we could cite: functional groups, non-
cyclic or cyclic and retroisosterism.  
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Monovalent Divalent Trivalent Tetravalent 
-OH, -NH2 – CH3, -OR -CH2- =CH- =c=
-F, -Cl, -Br, -I, -SH, -PH2 -O- =N- =Si=
-Si3, -SR -S- =P- =N+=
 -Se- =As- =As+=
 -Te- =Sb- =Sb+=
 =P+=
Table 1. Classic biososteres atoms and groups. 
The bioisosterism approach is an important molecular modification tool that allows the 
discovery of several drugs in the market. The drugs discovered using this strategy that are 
in the markets usually known as “me too” (Lima & Barreiro, 2005). 
This strategy has been used to discovery new compounds to treat tuberculosis. One example 
is the class of fluoquinolones. Fluoquinolones demonstrated, besides Gram-negative and 
Gram- positive activity, antitubercular activity. This class of drugs is known to inhibit 
bacterial DNA replication and transcription by binding to DNA-gyrase-DNA complex. The 
use of fluorquinolones occurs mainly in patients with multidrug-resistance (MDR). The 
most actives quinolones for the treatment of TB are: ciprofloxacin, sparfloxacin, ofloxacin, 
moxifloxacin and levofloxacin (Renau et al., 1996). Studies comparing the bactericidal 
activity of various fluoroquinolones against Mycobacterium tuberculosis in the latent and 
exponential growth phases.has demonstrated that most promising drugs are moxifloxacin 
and levofloxacin (Cremades et al., 2011). All these fluorquinolones drugs were obtained 
using bioisosteric replacement (Figure 13). 
 
Fig. 13. Fluorquinolones active against Mycobacterium tuberculosis. 
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Linezolid is oxazolidinone drug belonging of antibacterial agents used in the treatment of 
nosocomial pneumonia and uncomplicated and complicated skin and soft tissue infections 
caused by select Gram-positive bacteria (Ford et al., 2001). The drug has been evaluated in 
the treatment of MDR tuberculosis showing interesting results (Pinon et al., 2010). Based on 
this interesting result, some oxazolidinone biosisoteres have been developed. PNU-100480 is 
an analog of linezolid in clinical trial to be used in tuberculosis treatment (Leach et al 2011). 
Others linezolid derivatives such as radezolid and torelozid are obtained by isosteric 
replacement and these drugs are under clinical trial (Figure 14) (Leach et al 2011). 
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Fig. 14. Chemical structure of linezolid bioisosteric derivatives. 
 
Fig. 15. Some active and inactive oxazolidinone isosteres derivatives. 
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The isosteric replacement not always leads to equal or more active compounds. Sometimes 
isosteric replacement leads to inactive compounds. Snyder and co-workers do not found 
relationship between some heterocyclic rings with oxazolidinone present in linezolid. 
However, the same authors demonstrate an interesting relationship with other active 
compounds (Figure 15). In general, with bioisosteric approach it is possible to find at least 
one (or sometimes more) equivalent systems. 
Mycobacterium avium – intracellulare complex is one of the most common bacterial 
opportunistic in patients with AIDS. Clarithromycin and azithromycin are first-line agents 
for prevention and treatment. They are macrolide antibiotics which bacteriostatic activity 
due to bind to the 50S ribosomal unit (Wright, 1998). Azithomycin is a bioisoster of 
clarithromycin (Figure 16).   
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Fig. 16. Chemical structure of azithromycin and clarithromycin. 
 
Fig. 17. Ring bioisosteres of pyridine presenting in isoniazid. 
Bioisosteres of isoniazid has been designed exploring the bioisosteric replacement of 
pyridine ring to imidazo[1,2-α]-pyridine. However, the compound 2-methylimidazo[1,2- 
α]pyridine-3-carboxylic acid hydrazide demonstrate less antitubercular activity than 
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isoniazide (Kasimogullari & Cesur, 2004). The same results were observed by Santos and co-
workers after biosisoteric replacement of pyridine to 1,2,5-oxadiazole-2-oxide (furoxan) 
(unpublished results) (Figure 17). 
3. New drugs candidates for tuberculosis treatment 
Tuberculosis drug development efforts have emerged in the last years. Despite the progress, 
none new drugs were found in this last years. Ryfampicin, discovered 40 years ago, was the 
last novel antibiotic introduced for the first treatment of tuberculosis. The search for new 
targets in M. tuberculosis that might be inhibited to eliminate all known strains is a global 
pursuit.  
Several targets in M. tuberculosis have been reported. The inhibition of these targets could 
act in the growth and latent phase. Some targets in growth phase are GIgE (maltose 
metabolism), mycolic acid (mycolic acid metabolism), DprE1/DprE2 (cell wall metabolism), 
MshC (mycothiol ligase), HisG (histidine biosynthesis), AtpE (ATP synthesis), Def (protein 
processing), methionine aminopeptidase (protein processing). Some targets of dormant 
phase are isocitrate lyase (energy metabolism), proteosome complex (protein processing), 
L,D-transpeptidase (peptidoglycan metabolism), DosR (DevR) (regulation of dormancy) and 
CarD (stringent response) (Lamichhane, 2011). The most advances in new TB targets 
identification have been directed by the genome sequence of M. tuberculosis, however 
genome-derived target based approach have had little success until the present moment in 
the antibacterial class (Payne et al., 2007). 
The discovery new antitubercular drugs must possess some desired profile such as: broad 
spectrum of action acting against MDR-TB and XDR-TB; adequate and shorten treatment 
duration reducing pill burden in order to reduce numbers of pills taken; adequate 
pharmacokinetic profile in order to reduce drug-drug interaction (to be administered with 
HIV drugs), desired target tissue levels and allows long half-life of the drug (Koul et al, 
2011).   
N N
O
O
OH
H3C
H3C
nalidixic acid
N
O
O
OH
O
H3C
N
HN
CH3
F
N
O
O
OH
O
H3C
N
F
HN
H
H
gatifloxacin moxifloxacin  
Fig. 18. Moxifloxacin and gatifloxacin designed using nalidixic acid scaffold. 
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Currently the global TB development pipeline has nine candidates in different stages of 
clinical trial. These pipelines are: PNU 100480 (protein synthesis inhibitor), AZD 5847 
(protein synthesis inhibitor), SQ 109 (cell wall and multitarget inhibitor), OPC67683 (cell 
wall and multitarget inhibitor), PA824 (cell wall and multitarget inhibitor), gatifloxacin 
(DNA gyrase inhibitor), moxifloxacin (DNA gyrase inhibitor), TMC 207 (ATP synthase 
inhibitor) and sudoterb (mechanism still unknown). Some of them are active in latent and 
active form against MDR-TB and XD-TB (Koul et al., 2011). 
The most of currently pipeline TB drugs were developed using molecular modifications 
strategies. The fluorquinolones derivatives gatifloxacin and moxifloxacin were derivatized 
scaffolds from the parent nalidixic acid using the bioisosterism as molecular modification 
(Figure 18). 
The metronidazole scaffold was used to design PA-824 and OPC-67683 using bioisosterism 
and molecular hybridization (Figure 19).  
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Fig. 19. Nitroimidazole derivatives designed by molecular modification of metronidazole. 
The oxazolidinone derivative PNU-100480 was designed using linezolid as parent scaffold. 
This last one explored the bioisosterism as molecular modification tool (Figure 20).  
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Fig. 20. PNU-100480 derivative of oxazolidinones linezolid. 
The second line drug ethambutol was used as scaffold to develop the compound SQ109 
using bioisosterism and molecular hybridization (Figure 21). 
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Fig. 21. 1,2-ethylenediamine derivative SQ109 designed from ethambutol. 
4. Conclusion  
The molecular modification is an important tool to discover new compounds to treat 
Mycobacterium tuberculosis infection. The use of this strategy has allowed finding more 
active and safe compounds with wide spectrum, acting include against MDR and XDR 
tuberculosis. The most currently pipeline drugs for TB in clinical trial were developed using 
molecular modification demonstrating the importance of this strategy in antitubercular drug 
discovery new agents.   
5. References  
Albert, A. Chemical aspects of selective toxicity. Nature, (1958). Vol. 182, No. 4633, pp. 421-
423. 
Barry, C. E.; Blanchard, J. S. The chemical biology of new drugs in the development for 
tuberculosis. Current Opinion in Chemical Biology, (2010). V.14, No. 4, pp. 456-466. 
Burger, A. Isosterism and Bioisosterism in Drug Design. Progress in Drug Research, (1991). 
Vol. 37, pp. 287-371. 
Burger, A. Medicinal Chemistry, 3rd Ed., NY, EUA, Wiley, 1970, p. 127. 
Chung, M. C.; Ferreira, E. I.; Santos, J. L.; Giarolla, J.; Rando, D. G.; Almeida, A. E.; Bosquesi, 
P. L.; Menegon, R. F.; Blau, L., Prodrugs for the treatment of neglected diseases. 
Molecules, (2007). Vol. 13, No. 3, pp. 616-677. 
Cremades, R.; Rodríguez, J. C.; García-Pachón, E.; Galiana, A.; Ruiz-García, M.; López, P.; 
Royo, G. Comparison of the bactericidal activity of various fluoroquinolones 
against Mycobacterium tuberculosis in an in vitro experimental model. Journal of 
Antimicrobial Chemotherapy, (2011). Jul 6. [Epub ahead of print]. 
Cynamon, M.; Gimi, R.; Gyenes, F.; Sharpe, C.; Bergmann, K.; Han, H.; Gregor, L.; Rapolu, 
R.; Luciano, G.; Welch, J. Pyrazinoic acid esters with broad spectrum in vitro 
antimycobacterial activity. Journal of Medicinal Chemistry, (1995). Vol. 38, No. 20, 
pp. 3902–3907. 
Erlenmeyer, H.; Leo, M. On pseudoatoms. Helvetica Chimica Acta, (1932). Vol. 15, No. 1, pp. 
1171-1186. 
Ford, C. W., G. E.; Zurenko, M. R. & Barbachyn. The discovery of linezolid, the first 
oxazolidinone antibacterial agent. Current Drug Targets Infectious Disorders, 
(2001). Vol. 1, pp. 181–199. 
Gideon, H. P. Flynn J. L. Latent tuberculosis: what the host "sees"? Immunology Research, 
(2011). Vol. 50, No. 2-3, pp. 202-212. 
Gordon, S.; Rabinowitz, S. Macrophages as targets for drug delivery. Advanced Drug 
Delivery Reviews, (1989). Vol. 4, pp. 27–47. 
www.intechopen.com
 
Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance 
 
184 
Grimm, H. G. Structure and size of the non-metallic hybrids. Z. Eletrochem. (1925). Vol. 31, 
pp. 474-480. 
Harper, N. J. Drug latentiation. Journal Medicinal and Pharmaceutical Chemistry, (1959). 
Vol. 1, No. 5, pp. 467-500. 
Johnsson, K.; King, D. S.; Schultz, P. G. Studies on the mechanism of action of isoniazide and 
ethimamide in the chemotherapy of tuberculosis. Journal of the American 
Chemical Society, (1995). Vol. 117, No. 17, pp. 5009-5010. 
Kasimogullari, B. O.; Cesur, Z. Fused heterocycles: síntesis of some new imidazo[1,2-α]-
pyridine derivatives. Molecules. 2004, 9: 894-901. 
Kathleen, P. Martindale: The Complete Drug Reference, 32nd Edn.; Pharmaceutical Press: 
Chicago, USA, 1999, p. 151. 
Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery 
for tuberculosis. Nature, (2011). Vol. 469, No. 7331, pp. 483-90. 
Lalloo, U.G.; Ambaram, A. New antituberculous drugs in development. Curruent 
HIV/AIDS Reports, (2010). Vol. 7,  No. 3, pp. 143-151. 
Lamichchane, G. Novel targets in M. tuberculosis: search for new drugs. Trends in 
Molecular Medicine, (2011). Vol. 17, No. 1, pp. 25-33. 
Leach, K. L.; Brickner, S. J.; Noe, M. C.; Miller, P. F. Linezolid, the first oxazolidinone 
antibacterial agent. Annals of the New York Academy Sciences. (2011). Vol. 1222, 
No. 1, pp. 49-54.  
Lima, L. M.; Barreiro, E. J. Bioisosterism: A Useful Strategy for Molecular Modification and 
Drug Design. Current Medicinal Chemistry, (2005). Vol. 12, No. 1, pp. 23-49. 
Ma, Z.; Lienhardt, C.; McIlleron, H.; Nunn, A. J.; Wang, X. Global tuberculosis drug 
development pipeline: the need and the reality. The Lancet, (2010). Vol. 375, No. 
9731, pp. 2100-2109.  
Mdluli, K.; Sherman, D. R.; Hickey, M. J.; Kreiswirth, B. N.;  Morris, S.;  Stover, C. K.; Barry, 
C. E 3rd. Biochemical and genetic data suggest that inhA is not the primary target 
for activated isoniazid in Mycobacterium tuberculosis. Journal Infectious Diseases, 
(1996). Vol. 174, No. 5 pp. 1085-1090. 
Morphy, J. R.; Rankovic, Z. Fragments, network biology and designing multiple ligands. 
Drug Discovery Today, (2007). Vol. 12, No. 3-4, pp. 156-160. 
Morphy, J. R.; Rankovic, Z. The physicochemical challenges of designing multiple ligands. 
Journal Medicinal Chemistry, (2006). Vol. 49, No. 16, pp. 4961-4970.  
Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: 
confronting the challenges of antibacterial discovery. Nature Reviews Drug 
Discovery, (2007). Vol. 6, pp. 29–40.  
Pinon, M.; Scolfaro, C.; Bignamini, E.; Cordola. G.; Esposito, I.; Milano, R.; Mignone, F.; 
Bertaina, C.; Tovo, P. A. Two pediatric cases of multidrug-resistant tuberculosis 
treated with linezolid and moxifloxacin. Pediatrics, (2010). Vol. 126, No. 5, pp. 1253-
1256. 
Prateek, J. R.; Jaim, K.; Ravichandran, V.; Agrawal, R. K. Synthesis and evaluation of mutual 
prodrugs of isoniazid, p-amino salicylic acid and ethambutol. Arkivoc, (2007). (i), 
pp. 105–118. 
Renau, T. E.; Sanchez, J. P.; Gage, J. W.; Dever, J. A.; Shapiro, M. A.; Gracheck, S. J.; 
Domagala, J. M. Strucuture-activity relashionship of the quinolone antibacterial 
www.intechopen.com
 
New Antitubercular Drugs Designed by Molecular Modification 
 
185 
against mycobacteria: effect of strucutural changes at N-1 and C-7. Journal of 
Medicinal Chemistry, (1996). Vol. 39, No. 6, pp. 729-735. 
Roseeuw, E.; Coessens, V.; Balazuc, A-M.; Lagranderie, M.; Chavarot, P.; Pessina, A.; Néri, 
M. G.; Schacht, E.; Marchal, G.; Domurado, D. Synthesis, Degradation, and 
Antimicrobial Properties of Targeted Macromolecular Prodrugs of Norfloxacin. 
Antimicrobial Agents Chemotherapy, (2003). Vol. 47, No. 11, pp. 3435–3441. 
Santos, J. L.; Yamasaki, P. R.; Chin, C. M.; Takashi, C. H.; Pavan, F. R.; Leite, C. Q. Synthesis 
and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide 
derivatives. Bioorganic Medicinal Chemistry, (2009). Vol. 17, No. 11, pp. 3795-3799.  
Seitz, L. E.; Suling, W. J.; Reynolds, R. C. Synthesis and antimycobacterial activity of 
pyrazine and quinoxaline derivatives. Journal of Medicinal Chemistry, (2002). Vol. 
45, No. 25, pp. 5604-5606.  
Shindikar, A. V.; Viswanathan, C. L. Novel fluoroquinolones: design, synthesis, and in vivo 
activity in mice against Mycobacterium tuberculosis H37Rv. Bioorganic Medicinal 
Chemistry Letters, (2005). Vol. 15, No. 7, pp. 1803-1806. 
Silva M.; Lara, A. S.; Leite, C. Q.; Ferreira, E. I. Potential tuberculostatic agents: micelle-
forming copolymer poly(ethylene glycol)-poly(aspartic acid) prodrug with 
isoniazid. Archiv der Pharmazie, (2001). Vol. 334, No. 6, pp. 189-193. 
Silva, A. T. A.; Castro, L. F.; Guido, R. V. C.; Chung, M. C.; Ferreira, E.I. Advances in 
prodrug design. Mini-Reviews in  Medicinal Chemistry, (2005). Vol. 5, No. 10, pp. 
893–914. 
Simões, M. F.; Valente, E.; Gómez, M. J; Anes, E.; Constantino, L. Lipophilic pyrazinoic acid 
amide and ester prodrugs stability, activation and activity against M. tuberculosis. 
European Journal Pharmaceutical Sciences, (2009). Vol. 37, No. 3-4, pp. 257-263. 
Snyder, L. B.; Meng, Z.; Mate, R.; D'Andrea, S, V.; Marinier, A.; Quesnelle, C. A.; Gill, P.; 
DenBleyker, K. L.; Fung-Tomc, J. C.; Frosco, M.; Martel, A.; Barrett, J. F.; Bronson, J. 
J. Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the 
stereogenic center found in oxazolidinone antibacterials. Bioorganic Medicinal 
Chemistry Letters, (2004). Vol. 14, No. 18, pp. 4735-4739. 
Sriram, D.; Yogeeswari, P.; Gopal, G. Synthesis, anti-HIV and antitubercular activities of 
lamivudine prodrugs. Eurpean Journal Medicinal Chemistry, (2005). Vol. 40, No. 
12, pp. 1373–1376. 
Sriram, D.; Yogeeswari, P.; Narasimharaghavan, S.; Bai, T. R. Synthesis of tavudine amino 
acid ester prodrugs with broad-spectrum chemotherapeutic properties for the 
effective treatment of HIV/AIDS. Bioorganic Medicinal Chemistry Letters, (2004). 
Vol. 14, No. 5, pp. 1085–1087. 
Sriram, D.; Yogeeswari, P.; Reddy, S. P. Synthesis of pyrazinamide Mannich bases and its 
antitubercular properties. Bioorganic Medicinal Chemistry Letters, (2006). Vol. 16, 
No. 8, pp. 2113-2116.  
Thornber, C. W. Isosterism and molecular modification in drug design. Chemical Society 
Reviews, (1979). Vol. 8, No. 4, pp. 563-580. 
WHO. Global tuberculosis control: key findings from the December 2009 WHO report. Wkly 
Epidemiological Record, (2010). Vol. 85, No. 9, pp. 69–80. 
Wright, J. Current strategies for the prevention and treatment of disseminated 
Mycobacterium avium complex infection in patients with AIDS. Pharmacoteraphy, 
(1998). Vol. 32, pp. 561-573. 
www.intechopen.com
 
Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance 
 
186 
Zhang, Y. The magic bullets and tuberculosis drug targets. Annual Review of Pharmacology 
and Toxicology, (2005). Vol. 45, pp. 529–564. 
www.intechopen.com
Understanding Tuberculosis - New Approaches to Fighting
Against Drug Resistance
Edited by Dr. Pere-Joan Cardona
ISBN 978-953-307-948-6
Hard cover, 376 pages
Publisher InTech
Published online 15, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
In 1957, a Streptomyces strain, the ME/83 (S.mediterranei), was isolated in the Lepetit Research Laboratories
from a soil sample collected at a pine arboretum near Saint Raphael, France. This drug was the base for the
chemotherapy with Streptomicine. The euphoria generated by the success of this regimen lead to the idea that
TB eradication would be possible by the year 2000. Thus, any further drug development against TB was
stopped. Unfortunately, the lack of an accurate administration of these drugs originated the irruption of the
drug resistance in Mycobacterium tuberculosis. Once the global emergency was declared in 1993, seeking out
new drugs became urgent. In this book, diverse authors focus on the development and the activity of the new
drug families.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Jean Leandro dos Santos, Luiz Antonio Dutra, Thais Regina Ferreira de Melo and Chung Man Chin (2012).
New Antitubercular Drugs Designed by Molecular Modification, Understanding Tuberculosis - New Approaches
to Fighting Against Drug Resistance, Dr. Pere-Joan Cardona (Ed.), ISBN: 978-953-307-948-6, InTech,
Available from: http://www.intechopen.com/books/understanding-tuberculosis-new-approaches-to-fighting-
against-drug-resistance/new-antitubercular-drugs-designed-by-molecular-modification
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
